Xiaoyun Cheng

3.0k total citations
78 papers, 1.6k citations indexed

About

Xiaoyun Cheng is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Xiaoyun Cheng has authored 78 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 17 papers in Surgery and 16 papers in Oncology. Recurrent topics in Xiaoyun Cheng's work include Liver Disease Diagnosis and Treatment (6 papers), Diabetes and associated disorders (5 papers) and Bariatric Surgery and Outcomes (5 papers). Xiaoyun Cheng is often cited by papers focused on Liver Disease Diagnosis and Treatment (6 papers), Diabetes and associated disorders (5 papers) and Bariatric Surgery and Outcomes (5 papers). Xiaoyun Cheng collaborates with scholars based in China, United States and Taiwan. Xiaoyun Cheng's co-authors include Mien‐Chie Hung, Shen Qu, Dihua Yu, Weiya Xia, Gabriel N. Hortobágyi, Ming Tan, Yan M. Li, Binhua P. Zhou, Yongkun Wei and Xiaoyan Zhou and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Xiaoyun Cheng

74 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoyun Cheng China 21 590 572 300 209 207 78 1.6k
Jianping Zhang China 19 427 0.7× 469 0.8× 364 1.2× 243 1.2× 199 1.0× 67 1.6k
Hideki Amano Japan 26 451 0.8× 570 1.0× 230 0.8× 182 0.9× 146 0.7× 74 1.8k
Pawan Kumar United States 24 761 1.3× 869 1.5× 303 1.0× 162 0.8× 145 0.7× 64 1.9k
Georgia Levidou Greece 25 377 0.6× 823 1.4× 216 0.7× 294 1.4× 125 0.6× 92 1.8k
Chiara Mignogna Italy 26 340 0.6× 500 0.9× 203 0.7× 290 1.4× 136 0.7× 96 1.7k
Anargyros Xenocostas Canada 26 365 0.6× 797 1.4× 379 1.3× 108 0.5× 130 0.6× 109 2.4k
Juan A. Recio Spain 23 526 0.9× 1.0k 1.8× 179 0.6× 296 1.4× 133 0.6× 53 1.8k
Ki Cheol Park South Korea 23 333 0.6× 673 1.2× 150 0.5× 180 0.9× 124 0.6× 49 1.4k
Kohei Shomori Japan 24 397 0.7× 775 1.4× 155 0.5× 217 1.0× 158 0.8× 66 1.6k
Myoung Jae Kang South Korea 23 684 1.2× 768 1.3× 245 0.8× 449 2.1× 344 1.7× 60 1.9k

Countries citing papers authored by Xiaoyun Cheng

Since Specialization
Citations

This map shows the geographic impact of Xiaoyun Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoyun Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoyun Cheng more than expected).

Fields of papers citing papers by Xiaoyun Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoyun Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoyun Cheng. The network helps show where Xiaoyun Cheng may publish in the future.

Co-authorship network of co-authors of Xiaoyun Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoyun Cheng. A scholar is included among the top collaborators of Xiaoyun Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoyun Cheng. Xiaoyun Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Xiangyu, Guoliang Jiang, Tingting Yao, et al.. (2025). Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages. International Immunopharmacology. 160. 114971–114971.
2.
3.
Zheng, Weicheng, et al.. (2024). Assessment of the antimicrobial and immunomodulatory activity of QS-CATH, a promising therapeutic agent isolated from the Chinese spiny frogs (Quasipaa spinosa). Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology. 283. 109943–109943. 3 indexed citations
4.
Zhang, Yuqin, Le Bu, Xiaoyun Cheng, et al.. (2023). Predictive Factors of Menstrual Recovery After Laparoscopic Sleeve Gastrectomy in Polycystic Ovary Syndrome Women with Obesity. Diabetes Metabolic Syndrome and Obesity. Volume 16. 1755–1766. 3 indexed citations
5.
Chu, Fuliang, Jingjing Cao, Jingwei Liu, et al.. (2023). Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. Journal for ImmunoTherapy of Cancer. 11(11). e007515–e007515. 9 indexed citations
6.
Huang, Xiu, Yali Han, Jie Yang, et al.. (2023). Sex-dependent impact of obesity on aggressiveness of papillary thyroid cancer. HORMONES. 23(2). 217–225.
7.
Li, Nannan, Bei Xu, Lei Gu, et al.. (2022). Development of a New Index Based on Preoperative Serum Lipocalin 2 to Predict Post-LSG Weight Reduction. Obesity Surgery. 32(4). 1184–1192. 2 indexed citations
8.
Su, Bin, Mingming Gao, Jiaqi Chen, et al.. (2021). Obesity-associated up-regulation of lipocalin 2 protects gastric mucosa cells from apoptotic cell death by reducing endoplasmic reticulum stress. Cell Death and Disease. 12(2). 221–221. 13 indexed citations
9.
Huang, Xiu, Guifang Li, Bei Xu, et al.. (2021). Lower Baseline Serum Triglyceride Levels Are Associated With Higher Decrease in Body Mass Index After Laparoscopy Sleeve Gastrectomy Among Obese Patients. Frontiers in Endocrinology. 12. 633856–633856. 7 indexed citations
10.
11.
Nastoupil, Loretta J., Jason R. Westin, Nathan Fowler, et al.. (2017). High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study. Blood. 130. 414–414. 14 indexed citations
12.
Cheng, Xiaoyun, Li Li, Philip E. Thorpe, et al.. (2016). Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Annals of Surgical Oncology. 23(S5). 583–591. 22 indexed citations
13.
Pan, Shujuan, et al.. (2013). ERManI Is a Target of miR-125b and Promotes Transformation Phenotypes in Hepatocellular Carcinoma (HCC). PLoS ONE. 8(8). e72829–e72829. 20 indexed citations
14.
Pan, Shujuan, Xiaoyun Cheng, & Richard N. Sifers. (2013). Golgi-situated endoplasmic reticulum α-1, 2-mannosidase contributes to the retrieval of ERAD substrates through a direct interaction with γ-COP. Molecular Biology of the Cell. 24(8). 1111–1121. 44 indexed citations
15.
Wang, Chun, Li Hong, Jin‐Wei He, et al.. (2012). The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice. Journal of Bone and Mineral Metabolism. 30(6). 630–637. 29 indexed citations
16.
Su, Jen-Liang, Xiaoyun Cheng, Hirohito Yamaguchi, et al.. (2011). FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Research. 71(21). 6878–6887. 39 indexed citations
17.
Cheng, Xiaoyun, Weiya Xia, Jer-Yen Yang, et al.. (2010). Activation of Murine Double Minute 2 by Akt in Mammary Epithelium Delays Mammary Involution and Accelerates Mammary Tumorigenesis. Cancer Research. 70(19). 7684–7689. 16 indexed citations
18.
Su, Jen-Liang, Poshen B. Chen, Yi-Wen Chang, et al.. (2010). Downregulation of MicroRNA miR-520h by E1A Contributes to Anticancer Activity. Cancer Research. 70(12). 5096–5108. 51 indexed citations
19.
Cheng, Xiaoyun, Feng Zhang, Guangxin Zhou, et al.. (2009). DNA/chitosan nanocomplex as a novel drug carrier for doxorubicin. Drug Delivery. 16(3). 135–144. 12 indexed citations
20.
Cheng, Xiaoyun, Yan M. Li, Yong Pan, Yong Liao, & Mien‐Chie Hung. (2005). Downregulation of CXCR4 by E1A. Cancer Research. 65. 1331–1331. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianping Zhang Breakdown of academic impact, for papers by Hideki Amano Breakdown of academic impact, for papers by Pawan Kumar Breakdown of academic impact, for papers by Georgia Levidou Breakdown of academic impact, for papers by Chiara Mignogna Breakdown of academic impact, for papers by Anargyros Xenocostas Breakdown of academic impact, for papers by Juan A. Recio Breakdown of academic impact, for papers by Ki Cheol Park Breakdown of academic impact, for papers by Kohei Shomori Breakdown of academic impact, for papers by Myoung Jae Kang
Rankless by CCL
2026